Drug Information

Drug General Information
Drug ID
D03PGF
Former ID
DNC012702
Drug Name
RPR-118723
Drug Type
Small molecular drug
Indication Discovery agent Investigative [525816]
Formula
C14H11ClN2O4
Canonical SMILES
CC1(C2=C(C=C(C=C2)Cl)C3=C1NC(=O)C(=O)N3)CC(=O)O
InChI
1S/C14H11ClN2O4/c1-14(5-9(18)19)8-3-2-6(15)4-7(8)10-11(14)17-13(21)12(20)16-10/h2-4H,5H2,1H3,(H,16,20)(H,17,21)(H,18,19)
InChIKey
XNLOOYJBLRHTMX-UHFFFAOYSA-N
PubChem Compound ID
9796571
Target and Pathway
Target(s) Glutamate receptor 1 Target Info Inhibitor [525816]
NMDA receptor subunit NR1 Target Info Inhibitor [525816]
Glutamate [NMDA] receptor subunit epsilon 2 Target Info Inhibitor [525816]
Glutamate [NMDA] receptor subunit epsilon 1 Target Info Inhibitor [525816]
Glutamate receptor AMPA subtype Target Info Inhibitor [525816]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Circadian entrainment
Long-term potentiation
Retrograde endocannabinoid signaling
Glutamatergic synapse
Dopaminergic synapse
Long-term depression
Amyotrophic lateral sclerosis (ALS)
Amphetamine addiction
Nicotine addictionhsa04014:Ras signaling pathway
Rap1 signaling pathway
Calcium signaling pathway
Alzheimer's disease
Huntington's disease
Cocaine addiction
Nicotine addiction
Alcoholismhsa04014:Ras signaling pathway
Alcoholism
Systemic lupus erythematosushsa04014:Ras signaling pathway
Systemic lupus erythematosus
PANTHER Pathway Ionotropic glutamate receptor pathway
Metabotropic glutamate receptor group III pathwayP00029:Huntington disease
Metabotropic glutamate receptor group III pathway
Metabotropic glutamate receptor group I pathway
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00029:Huntington disease
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
Pathway Interaction Database EPHB forward signalingerbb4_pathway:ErbB4 signaling events
Reelin signaling pathwayreelinpathway:Reelin signaling pathway
Reactome COPII (Coat Protein 2) Mediated Vesicle Transport
Trafficking of AMPA receptors
Trafficking of GluR2-containing AMPA receptors
Unblocking of NMDA receptor, glutamate binding and activation
Cargo concentration in the ERR-HSA-3928662:EPHB-mediated forward signaling
CREB phosphorylation through the activation of CaMKII
Ras activation uopn Ca2+ infux through NMDA receptor
RAF/MAP kinase cascadeR-HSA-3928662:EPHB-mediated forward signaling
RAF/MAP kinase cascadeR-HSA-438066:Unblocking of NMDA receptor, glutamate binding and activation
RAF/MAP kinase cascade
WikiPathways Hypothetical Network for Drug Addiction
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
Amyotrophic lateral sclerosis (ALS)
BDNF signaling pathwayWP706:SIDS Susceptibility Pathways
Spinal Cord Injury
BDNF signaling pathway
Alzheimers DiseaseWP666:Hypothetical Network for Drug Addiction
BDNF signaling pathwayWP666:Hypothetical Network for Drug Addiction
Alzheimers Disease
References
Ref 525816J Med Chem. 2000 Jun 15;43(12):2371-81.Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity.
Ref 525816J Med Chem. 2000 Jun 15;43(12):2371-81.Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity.